Medtronic Data Backs MiniMed 780G for Type 2, Young Type 1 Diabetes Patients

Medtronic will present data at the American Diabetes Association (ADA) 85^th Scientific Sessions that highlight improved glycemic outcomes for people with insulin-intensive type 2 diabetes on the MiniMed 780G system under investigational use.

Subjects in a clinical trial had an average 8.6% increase in Time in Range (TIR), reaching 84.9% above the ADA goal of 70%. Data also showed an HbA1C reduction from 7.7% to 6.9% to meet ADA targets for diabetes management.

In this trial, 236 patients with type 2 diabetes were evaluated at 31 sites. In addition to TIR improvements, results were promising for Time in Tight Range (TITR) and Time Above Range (TAR) compared the run-in period where hybrid closed loop (auto basal only) or open-loop delivery was used.

“As the industry moves toward broader indications of automated insulin delivery systems, we see tremendous potential to improve outcomes and quality of life for millions of people managing type 2 diabetes with insulin,” said Dr. Robert Vigersky, Chief Medical Officer, Medtronic Diabetes. “Our teams are committed to advancing smart, connected technologies that reduce the daily burden of care and bring precision to insulin therapy like never before.”

Results from Medtronic’s LENNY trial were also published in The Lancet Diabetes & Endocrinology. The trial evaluated MiniMed 780G in children aged two to six with type 1 diabetes in a home setting. Data demonstrated those using MiniMed 780G with SmartGuard had 0.6% lower HbA1C and 9.9% higher TIR compared to baseline therapy of manual mode or hydrid closed loop without autocorrections.

“To preserve brain development and minimize long-term diabetes complications, it is essential that blood glucose concentrations are maintained close to healthy ranges from disease onset in early life,” said Prof. Tadej Battelino, MD, Head of Department of Pediatric and Adolescent Endocrinology, UMC Ljubljana, Slovenia. “We are hopeful that if the data continues to be strong, the MiniMed 780G system can help make this possible.”

MiniMed 780G isn’t currently indicated for use in type 2 diabetes or children under seven years old by the FDA or other regulatory agencies. Medtronic said it plans to work with regulators to expand access to its diabetes tech for insulin-intensive type 2 diabetes, and gain a lower age indication for those with type 1 diabetes.

Earlier this month, the company revealed the name for its planned New Diabetes Company following the intended separation will be MiniMed. This name hearkens back to the company’s roots, reflecting its original name before its acquisition by Medtronic in 2001.